Articles tagged "Co-stimulation"

2021 American Transplant Congress
Life-supporting Multi-gene Cardiac Xenografts From Swine Demonstrate Survival >8 Months and Preclinical Efficacy for Human Clinical Trials
C. Goerlich¹, B. Griffith¹, A. Singh¹, T. Zhang¹, I. Tatarov¹, B. Lewis¹, F. Sentz¹, A. Hershfeld¹, P. Odonkor¹, B. Williams¹, E. Strauss¹, A. Tabatabai², A. Bhutta³, D. Ayares⁴, D. Kaczorowski¹, M. Mohiuddin¹
¹Surgery, University of Maryland School of Medicine, Baltimore, MD, ²Department of Medicine, Division of Pulmonary and Critical Care Medicine, University of Maryland School of Medicine, Baltimore, MD, ³Pediatrics, Pediatric Critical Care Medicine, University of Maryland School of Medicine, Baltimore, MD, ⁴Revivicor, Inc., Blacksburg, VA
*Purpose: Cardiac xenotransplantation has been proposed to bridge the gap in organ shortage for those in end-stage heart failure without the opportunity to receive a…
2021 American Transplant Congress
Kidney Transplant Outcomes Stratified by Age with a Calcineurin and Steroid Free Regimen
R. Scalzo¹, M. Harris¹, J. Morris², J. Byrns¹
¹Pharmacy, Duke University Hospital, Durham, NC, ²Nephrology, Duke University Hospital, Durham, NC
*Purpose: To evaluate the impact of an alemtuzumab, belatacept, and sirolimus based regimen on renal function stratified by age in kidney transplant (KT) patients.*Methods: This…
2021 American Transplant Congress
Immunosuppression Reduction Strategies for Polyoma BK Viremia in Kidney Transplant Patients on Belatacept-Based Immunosuppression
O. Roe¹, E. Meredith¹, A. Reid², A. Basu³
¹Emory University Hospital, Atlanta, GA, ²University of California San Francisco Medical Center, San Francisco, CA, ³Emory Transplant Center, Atlanta, GA
*Purpose: The mainstay of treatment for BK infection is immunosuppression (IS) reduction, however limited literature provides guidance for treatment of patients with a belatacept-based IS…
2021 American Transplant Congress
Kidney Transplant Outcomes Stratified by Race with a Calcineurin and Steroid Free Regimen
R. E. Scalzo, M. T. Harris, J. D. Morris, J. S. Byrns
Pharmacy, Duke University Medical Center, Durham, NC
*Purpose: This study aimed to describe the outcomes, stratified by race, associated with belatacept and sirolimus immunosuppression after alemtuzumab induction.*Methods: This was a retrospective, single-center…
2021 American Transplant Congress
P40 Homodimers Induce Il-15 to Promote Endogenous Donor-reactive Memory Cd8 T Cell Activation within High-risk Cardiac Allografts
H. Tsuda, A. Valujskikh, R. Fairchild
Inflammation and Immunity, Cleveland Clinic, Cleveland, OH
*Purpose: Longer cold ischemic storage (CIS) time prior to transplant results in increased proliferation of endogenous donor-reactive memory CD8 T cells within complete MHC-mismatched cardiac…
2021 American Transplant Congress
Obesity Impacts Acute Rejection but Not Allograft Function Improvement in the Setting of Belatacept Conversion
D. Pierce, J. Benken, P. West-Thielke, I. Tzvetanov, E. Benedetti, A. Lichvar
University of Illinois at Chicago, Chicago, IL
*Purpose: There is limited data regarding belatacept conversion in obese patients as an alternative to calcineurin inhibitor (CNI) immunosuppression. Pharmacokinetic (PK) data suggests increasing clearance…
2021 American Transplant Congress
Belatacept Exposure Not Associated With Rejection. Can Doses be Lowered without Compromising Efficacy?
M. McGowan¹, A. Bickenbach¹, B. Miyagawa², A. Christianson¹, T. Mizuno², P. West-Thielke³, J. Leone⁴, E. Woodle¹, D. Kaufman⁵, A. Wiseman⁶, A. Matas⁷, A. Vinks², R. Alloway¹
¹U Cincinnati, Cincinnati, OH, ²Cincinnati Children's Med Center, Cincinnati, OH, ³U Illinois, Chicago, IL, ⁴Tampa Gen, Tampa, FL, ⁵U Wisconsin, Madison, OH, ⁶Centura Transplant, Denver, CO, ⁷U Minnesota, Minneapolis, MN
*Purpose: Phase 1 and 2 belatacept(BELA) pharmacokinetic(PK) studies informed dosing in phase 3 studies. PK data from these studies revealed higher BELA troughs on Day…
2021 American Transplant Congress
Association of Belatacept Conversion on Patient and Allograft Survival in Kidney Transplant Recipients with Congestive Heart Failure
H. Mogallapalli
Department of Medicine, University of Wisconsin-Madison, Madison, WI
*Purpose: Calcineurin inhibitors (CNI) exert deleterious effect on cardiovascular risk in kidney transplant recipients (KTRs). Belatacept conversion may reduce CV risk in KTRs. We hypothesized…
2021 American Transplant Congress
TIGIT Agonism Improves Immunosuppression of Cd8 T Cells by Ctla-4ig in a Treg Dependent Manner
C. R. Hartigan, D. Liu, M. L. Ford
Emory University Transplant Center, Emory University, Atlanta, GA
*Purpose: Costimulation blockade therapeutics for immunosuppression in transplant are less toxic than calcineurin inhibitors offering improved graft longevity and patient quality of life, but belatacept-resistant…
2021 American Transplant Congress
Tolerability of De Novo and Conversion Belatacept Regimens in Kidney Transplantation
T. Le¹, J. Shoji², J. Phillips¹, D. Quan¹
¹Pharmaceutical Services, UCSF Medical Center, San Francisco, CA, ²Transplant Nephrology, UCSF Medical Center, San Francisco, CA
*Purpose: Belatacept, a selective T lymphocyte co-stimulation blocker, has been shown to be a safe and effective maintenance therapy for immunosuppression. We investigated the long-term…

1
2
3
…
27
Next Page »